Lantern Pharma Unveils AI Module to Enhance Cancer Combination Therapies Development

Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has launched a new AI module within its RADR(R) platform aimed at predicting the effectiveness of combination therapies involving DNA-damaging agents and DNA damage response inhibitors. This innovation is supported by a comprehensive analysis of 221 clinical trials, offering a biomarker-guided approach to designing cancer treatment regimens that could reduce development time and costs by up to one-third. The technology has already played a pivotal role in designing Lantern’s FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, combining LP-184 and olaparib. Lantern Pharma is now looking into licensing and commercialization opportunities to expand the application of this system across various oncology indications.

The RADR(R) platform, Lantern Pharma’s proprietary AI and machine learning system, utilizes over 200 billion oncology-focused data points and more than 200 advanced ML algorithms to address challenges in oncology drug development. This approach has enabled Lantern to advance its drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, with an average cost of approximately $2.5 million per program. The launch of this new AI module marks a significant step forward in the company’s mission to transform the cost, pace, and timeline of oncology drug discovery and development.

For more details on Lantern Pharma’s latest advancements, visit https://ibn.fm/SWNHJ.